umifenovir (arbidol) - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical deterioration 0.86 [0.06, 11.36]< 10%1 study (1/-)54.6 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 0.18 [0.01, 3.99]> 10%1 study (1/-)14.3 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.08 [0.00, 1.71]> 10%1 study (1/-)5.5 %some concernnot evaluable moderateimportant-
viral clearance 2.80 [0.31, 25.53]> 10%1 study (1/-)81.8 %some concernnot evaluable moderateimportant-
viral clearance by day 14 2.80 [0.31, 25.53]> 10%1 study (1/-)81.8 %some concernnot evaluable moderateimportant-
viral clearance by day 7 0.67 [0.10, 4.58]> 10%1 study (1/-)34.1 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.